Treatment of dry age-related macular degeneration with Valeda from Lumithera
Athens EyeCare Clinic is proud to present Lumithera’s Valeda – an innovative treatment for dry age-related macular degeneration.
Valeda is one of the first of its kind in Athens, using advanced photobiomodulation (PBM) to improve visual function and maintain eye health.
What is age-related macular degeneration?
Dry age-related macular degeneration is one of the most common causes of irreversible vision loss in the elderly. It affects the macula, the neuro-sensory centre of clear vision, causing gradual destruction of the photoreceptors. Macular degeneration leads to progressive difficulty in reading. Until recently, there was no approved intervention for the dry form of the condition. Lumithera’s Valeda treatment introduces a new, non-invasive approach, offering hope for slowing progression and improving vision.
The condition progresses slowly but steadily. In its dry form, it is characterized by the accumulation of deposits (drusen) under the retina, which damages the normal functioning of the cells in the area. This condition, if not treated in time, can lead to irreversible loss of central vision. Treatment of dry form until recently, it was one of the most challenging problems in Ophthalmology.
Photobiomodulation technology with Lumithera's Valeda
The modern answer to the treatment of dry form of age related macular degeneration is photobiomodulation (PBM), a technique that uses light of specific wavelengths to activate cellular mechanisms. Lumithera’s Valeda Light Delivery System is the world’s first approved device for dry macular degeneration treatment.
The device emits blue, red and infrared light, which targets deep into the retina. These wavelengths:
- Enhance the mitochondrial function of cells.
- Improve local blood supply and oxygen transport.
- Reduce oxidative stress and inflammatory reactions.
- Promote the repair of damage under the retina.
- Help improve vision and delay the progression of the disease.
The treatment is applied in 9 short sessions within three weeks. It does not cause pain, does not require anaesthesia and has no recovery time. Patients can resume immediately their daily activities.
Treatment with Lumithera's Valeda: Scientific data and FDA approval
The effectiveness of Valeda treatment is documented by many multi-centre clinical studies. Over a period of two years, the participants showed a clear improvement in vision and a stabilization of the progression of age-related macular degeneration. The researchers found a reduced rate of development of geographic atrophy, which signalled a scientific progress.
In 2023, the device received official approval from the FDA (American Drug Administration). This is the first time that a non-invasive photobiomodulation technology has been used with such systematic use in the treatment of dry age-related macular degeneration. The approval was based on documented safety and repeatability of results.
Valeda treatment is now integrated into treatment protocols internationally, offering patients a reliable option that changes the prognosis of the condition.
Lumithera’s Valeda Treatment: Advantages
This new treatment has an advantage over traditional methods:
- It does not require any medication or injection into the eye.
- It is safe and painless for all patients.
- It can be repeated without causing damage to the tissues.
- It affects the cellular level, enhancing the natural regenerative capacity of the eye.
- Improves functional results without surgery.
It is noteworthy that, in several cases, the improvement in vision remains stable for months after the completion of the treatment. Patients report a better quality of life, greater autonomy and increased self-confidence in their daily lives.
Which patients can benefit from the treatment?
Treatment of the dry form is mainly indicated for people with early or intermediate dry age-related macular degeneration. It can also be applied in cases of mild geographic atrophy, before the complete loss of the central visual field.
Inclusion in the treatment is determined by the attending Ophthalmologist after a complete examination, which includes macular OCT and digital fundus photography. Patients with wet-type macular degeneration or severe macular lesions are not indicated for this protocol.
The patient’s cooperation, regular follow-ups and consistency in the process are decisive factors for the long-term success of the treatment.
Lumithera Treatment: A New Era in Preventing Vision Loss
Lumithera’s photobiomodulation (PBM) technology is not just an additional option, but a new philosophy in approaching macular degeneration. Instead of waiting for it to worsen, it can intervene in time and enhance the retina’s natural defence functions.
Early intervention with Valeda offers the possibility of preventing vision loss before it develops into disability. Treatment does not replace other medical interventions, but works as a complement and protective, especially in the early stages of the disease.
The wide range of safety, simplicity of the procedure and its effectiveness create new standards of care for ophthalmology patients.
Why choose Athens EyeCare Clinic?
We are one of the first clinics in Athens to offer Valeda treatment, with a well-trained team dedicated to providing the best care.
Our practice focuses on scientific excellence, compassion, and technological innovation, ensuring that you receive the highest level of care.
Summary:
Dry age-related macular degeneration is challenging, but Valeda offers new hope.
The Athens EyeCare Clinic is at the forefront of innovation, helping people with dry age-related macular degeneration maintain their vision and independence.
